Transplant diagnostics firm CareDx Q3 revenue beats estimates, helped by new product launches

CareDx

04/11/2025 21:41

Overview

CareDx Q3 revenue rose 21% yr/yr, beating analyst expectations

Adjusted EPS for Q3 beats consensus, reflecting strong operational performance

Company raised 2025 revenue guidance to $372 mln-$376 mln

Outlook

CareDx raises 2025 revenue guidance to $372 mln to $376 mln

Company increases 2025 adjusted EBITDA guidance to $35 mln to $39 mln

Result Drivers

TESTING SERVICES - Testing services revenue increased 19% yr/yr, driven by a 13% rise in testing volume

NEW PRODUCT LAUNCHES - Introduction of AlloSeq Tx11 and HistoMap Kidney supported revenue growth

INNOVATION IN TRANSPLANT SOLUTIONS - New products like HistoMap Kidney and AlloSure Heart contributed to growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$100 mln
$95.25 mln (8 Analysts)
Q3 Adjusted EPS
Beat
$0.28
$0.14 (6 Analysts)
Q3 EPS
$0.03
Q3 Adjusted Net Income
Beat
$14.90 mln
$7.48 mln (6 Analysts)
Q3 Net Income
$1.70 mln
Q3 Adjusted EBITDA
Beat
$15.30 mln
$7.93 mln (6 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for CareDx Inc is $23.00, about 35.8% above its November 3 closing price of $14.77

The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 16 three months ago

Press Release: ID:nBw84W8T5a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)